

Using the glossary (term base)

While translating, you can add important, recurring terms to the glossary, the so-called Term base. You can do this by selecting a term in the English source text or your translation and then clicking the "Add term" button in the quick access toolbar (or by clicking "Alt + T").

A new window will open at the bottom where you can add the corresponding translation and optionally include additional information such as whether the term is case-sensitive, preferred or forbidden. Then click "Add".

The screenshot shows the Phrase Editor interface. At the top, there's a toolbar with various icons, including a red box highlighting the 'Add term' icon (a document with a plus sign). Below the toolbar, there's a table with 5 rows of text. The first row is highlighted. Below the table, there's a 'Context note' and a 'Preview' tab. The 'Preview' tab is active, showing a large text box with the following text: **Intervenciones farmacológicas para la prevención de las hemorragias en personas sometidas a cirugía programada de cadera o rodilla: revisión sistemática y metanálisis en red**. Below this text box, there's a label 'Original title: Pharmacological interventions for the prevention of bleeding in people undergoing elective hip or knee surgery: a systematic review and network meta-analysis'. At the bottom, there's a red-bordered box labeled 'Add term'. Inside this box, there are two input fields: 'Source term' (containing 'interventions') and 'Target term' (containing 'es'). Below these fields, there are checkboxes for 'Case sensitive', 'Preferred', and 'Forbidden'. There are also radio buttons for 'Fuzzy match' (selected) and 'Exact match'. An 'Add' button is located to the right of the checkboxes.

Alternatively, you can add terms by going to "Term bases" in the left-hand navigation and then selecting the glossary for your language.

The screenshot shows the 'Term bases' interface in the Phrase application. On the left, there's a sidebar with a list of navigation items: 'Projects', 'Jobs', 'Translation memories', 'Term bases' (highlighted with a red box), 'Users', 'Phrase Language AI', 'Phrase Analytics', 'Submitter portal', and 'Settings'. The main area is titled 'Term bases' and contains a table with 2 columns: '# Name' and 'Languages'. The table has one row with the number '34' in the first column and 'German glossary' in the second column. The 'German glossary' text is highlighted with a red box. To the right of the table, there's a dropdown menu for 'Languages' with 'de' and 'en' options.

Next, click on "New" to add an English term and the equivalent translation in your language. Then click "Add".

German glossary


34 Languages de en


Name German glossary Terms 2077


Created by judith.deppe Business unit German

Created Sep 30, 2021

Owner judith.deppe

Last Import 

Terms  New

German  Search Reset

| Language | Term | Status |
|----------|----------------------|--------|
| de | <input type="text"/> | |
| en | <input type="text"/> | |

Cancel Add

You can make changes to the saved terms or add additional information by clicking on the term that you would like to change.

If you would like to add a list of terms, you can do that by using the "Import" button and uploading an Excel sheet with two columns. For further details, please get in touch with Judith (jdeppe@cochrane.org).

While translating you will see terms that are included in the glossary (term base), marked in yellow in the English source text. In the CAT panel on the right-hand side, terms from the glossary (term base) are marked with a yellow TB. The red TB label stands for forbidden terms (see screenshot below).

You can easily insert the terms into the segment that you are working on by double-clicking the term in the CAT panel.

| | | | | |
|----|--|--|----|--|
| | transfusion. | para reducir el riesgo de transfusión sanguínea. | | |
| 29 | We were unable to perform an NMA for our primary outcome all-cause mortality within 30 days of surgery due to the large number of studies with zero events or because the outcome was not reported. | No fue posible realizar un MAR para el desenlace principal de mortalidad por todas las causas dentro de los 30 días de la cirugía debido al gran número de estudios con cero eventos o porque no se informó el desenlace. | 77 | |
| 30 | In the NMA for deep vein thrombosis (DVT), we included 19 studies (2395 participants). | En el MAR para la trombosis venosa profunda (TVP), se incluyeron 19 estudios (2395 participantes). | 65 | |
| 31 | Most studies examined TXA (27 arms, 64%). | La mayoría de los estudios examinaron el ATX (27 grupos, 64%). | 55 | |
| 32 | No studies assessed desmopressin, EACA or topical fibrin. | Ningún estudio evaluó la desmopresina, el EACA ni la fibrina tópica. | 61 | |
| 33 | We found that TXA given intravenously and orally at a total dose of greater than 3 g intraoperatively and postoperatively ranked the highest, with an anticipated absolute effect of 67 fewer DVTs per 1000 people (67 fewer to 34 more) (26% chance of ranking first) within the NMA (RR 0.16, 95% CrI 0.02 to 1.43; low-certainty evidence). | Se encontró que el ATX administrado por vía intravenosa y oral a una dosis total de más de 3 g intraoperatoria y posoperatoria ocupó el primer lugar, con un efecto absoluto previsto de 67 TVP menos por cada 1000 personas (67 menos a 34 más) (26% de probabilidad de ocupar el primer lugar) dentro del MAR (RR 0.16; IC del 95% 0.02 a 1.43; evidencia de certeza baja). | 83 | |
| 34 | This was followed by TXA given intravenously and intra-articularly at a total dose of 2 g pre-incision and intraoperatively (RR 0.21, 95% CrI 0.00 to 9.12; low-certainty evidence) and TXA given intravenously and intra-articularly, total dose greater than 3 g pre-incision, intraoperatively and postoperatively (RR 0.13, 95% CrI 0.01 to 3.11; low-certainty evidence). | Este estuvo seguido por la administración de ATX por vía intravenosa e intraarticular a una dosis total de 2 g antes de la incisión y durante el posoperatorio (RR 0.21; IC del 95%: 0.00 a 9.12; evidencia de certeza baja) y de ATX por vía intravenosa e intraarticular a una dosis total superior a 3 g antes de la incisión, durante el posoperatorio y durante el posoperatorio (RR 0.13; IC del 95%: 0.01 a 3.11; evidencia de certeza baja). | 85 | |
| 35 | Aprotinin was not shown to be as effective compared with TXA (RR 0.67, 95% CrI 0.28 to 1.62; very low-certainty evidence). | La aprotinina no demostró ser tan eficaz en comparación con el ATX (RR 0.67; IC del 95% 0.28 a 1.62; evidencia de certeza muy baja). | 73 | |
| 36 | We were unable to perform an NMA for our secondary outcome all-cause mortality within 30 days of surgery due to the large number of studies with zero events or because the outcome was not reported. | No fue posible realizar un MAR para el desenlace secundario de mortalidad por todas las causas dentro de los 30 días de la cirugía debido al gran número de estudios con cero eventos o porque no se informó el desenlace. | 77 | |

| CAT | |
|--|---|
| 1 We were unable to perform an NMA for our primary outcome all-cause mortality within 30 days of surgery due to the large number of studies with zero events, or because the outcome was not reported. | 101 No fue posible realizar un MAR para el desenlace principal de mortalidad por todas las causas dentro de los 30 días de la cirugía debido al gran número de estudios con cero eventos o porque no se informó el desenlace. |
| 2 primary outcome | 19 desenlace principal |
| 3 surgery | 19 cirugía |
| 4 events | 19 episodios |
| 5 event | 19 episodio |
| 6 event | 19 evento |
| 7 report | 19 comunicar* |
| 8 report | 19 informar* |
| 9 report | 19 notificar |
| 10 report | 19 reportar |
| 11 All-cause mortality | 5 Mortalidad por todas las causas |
| 12 All-cause mortality | 5 mortalidad por todas las causas |
| 13 All-cause Mortality | 5 Mortalidad por todas las causas |
| 14 number of studies | 5 Cantidad de estudios |
| 15 Primary outcome | 5 Medida de resultado primaria |